Biotech vet Cooper joins Repligen’s board

Video Gallery

MHT's Julie Donnelly: Life science startups finding investments

MHT's Galen Moore: Hiring trends and opportunities

MHT managing editor Rodney Brown on NECN: 22 tech companies give back to community

Related News

Zalicus, Hydra team up on pain treatment [February 10, 2012]

Ironwood stock offering aims for $80M [February 10, 2012]

Forsyth gets $750K grant from Gates Foundation [February 9, 2012]

Leonardi named Connecticut Innovations CEO [February 9, 2012]

Hyatt leaves the Farmville for Spark Capital [February 9, 2012]

Repligen Corp., a Waltham developer of biopharmaceuticals, has elected biotechnology entrepreneur and medical doctor Glenn Cooper to its board of directors.

Cooper was formerly the chairman and chief executive officer of Indevus Pharmaceuticals Inc. in Lexington. Indevus was acquired in March by Endo Pharmaceuticals Holdings (Nasdaq: ENDP), based in Chadds Ford, Pa.

Cooper received an M.D. from Tufts University School of Medicine and a bachelor’s degree from Harvard College.

Last November, Repligen began a Phase 2b clinical trial of its bipolar depression treatment, RG2417.

The company announced last September that it had received just over $1 million in research grants, awarded predominantly through the Muscular Dystrophy Association, in addition to the Friedreich’s Ataxia Research Foundation and the National Ataxia Foundation, to develop tools to help create new treatments for the rare neurodegenerative disease Friedreich’s Ataxia.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.